Site Registration
Registration benefits include:
- Access to CME/CE programs
- Free subscription to Current Medical Evidence
- Reminders of new CME/CE activities
About This Section
Access a regularly updated listing of late-stage clinical trials of high relevance to clinicians who provide care to patients who have or are at risk for osteoporosis. Featured in the most recent update are studies on postmenopausal osteoporosis, secondary osteoporosis, osteoporosis in men, hip and vertebral fracture prevention, and therapeutic agents such as bisphosphonates, calcitonin, denosumab, estrogen, odanacatib, parathyroid hormone analogs, estrogen receptor agonists/antagonists, and other drugs in development.
Parathyroid Hormone
PTH & Ibandronate Combination Study (PICS)
Condition: Osteoporosis
Interventions: Drug: PTH(1-84); Drug: Ibandronate
Sponsor: University of California, San Francisco
Active, not recruiting - verified August 2009
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Postmenopausal
Interventions: Drug: teriparatide; Drug: teriparatide; Drug: Placebo; Drug: Calcium Supplement; Drug: Vitamin D Supplement
Sponsor: Eli Lilly and Company
Completed - verified April 2008
Bone Properties in Hypoparathyroidism: Effects of PTH
Condition: Hypoparathyroidism
Intervention: Drug: PTH
Sponsors: Columbia University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2010
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
Condition: Osteoporosis
Intervention: Drug: Parathyroid Hormone (PTH)
Sponsor: Nycomed
Recruiting - verified August 2010
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
Condition: Osteoporosis Postmenopausal
Intervention: Drug: Risedronate (HMR4003)
Sponsors: Sanofi-Aventis; Procter and Gamble
Completed - verified December 2009
Calcium and Vitamin D Malnutrition in Elderly Women
Conditions: Osteoporosis; Secondary Hyperparathyroidism
Interventions: Dietary Supplement: calcium supplementation; Dietary Supplement: calcium and vitamin D3 supplementation; Dietary Supplement: Placebo
Sponsors: Creighton University; GlaxoSmithKline
Completed - verified August 2008
Calcium Supplementation in Postmenopausal Women
Condition: Osteoporosis
Intervention: Drug: ALX1-11
Sponsor: NPS Pharmaceuticals
Completed - verified August 2008
Open Label Extension Study of PREOS
Condition: Osteoporosis
Intervention: Drug: ALX1-11 (drug)
Sponsor: NPS Pharmaceuticals
Completed - verified August 2008
TOP: Trial of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Condition: Osteoporosis
Intervention: Drug: ALX1-11
Sponsor: NPS Pharmaceuticals
Completed - verified September 2005
TRES
Condition: Osteoporosis
Intervention: Drug: ALX1-11
Sponsor: NPS Pharmaceuticals
Active, not recruiting - verified September 2005
Once Weekly Parathyroid Hormone for Osteoporosis
Conditions: Osteopenia; Osteoporosis
Interventions: Drug: Teriparatide; Drug: Placebo teriparatide
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed - verified December 2007
Effects of Parathyroid Hormone in Men With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Parathyroid hormone; Drug: Alendronate
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed - verified February 2008
